Vanta Diagnostics provides molecular diagnostic and anatomical pathology services through a national CLIA- and CAP-certified laboratory. The company focuses on rapid molecular pathogen detection, semi-quantification, and resistance gene identification to support antibiotic stewardship. Its test menu includes targeted PCR-based panels for respiratory, urinary, gastrointestinal, wound, nail, joint, dermatologic, surgical, STI, and vaginal infections, along with pharmacogenetic testing and COVID-19 assays. Vanta Diagnostics serves healthcare providers across 45 U.S. states and delivers results in less than 24 hours from specimen arrival, supported by PharmD guidance and electronic result delivery options.